Nanomedicine targeting brain lipid metabolism as a feasible approach for controlling energy balance

Targeting brain lipid metabolism is a promising strategy to regulate the energy balance and fight metabolic diseases such as obesity. The development of stable platforms for selective delivery of drugs, particularly to the hypothalamus, is a challenge but a possible solution for these metabolic dise...

Descripción completa

Detalles Bibliográficos
Autores: García-Chica, Jesús, Paraiso, West Kristian D., Zagmutt Caroxa, Sebastián, Fosch, Anna, Reguera, Ana Cristina, Alzina, Sara, Sánchez García, Laura, Fukushima, Shigeto, Toh, Kazuko, Casals, Núria, Serra i Cucurull, Dolors, Herrero Rodríguez, Laura, García Gómez, Jordi, Kataoka, Kazunori, Ariza Piquer, Xavier, Quader, Sabina, Rodríguez Rodríguez, Rosalía
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/196203
Acceso en línea:https://hdl.handle.net/2445/196203
Access Level:acceso abierto
Palabra clave:Metabolisme
Medicaments
Metabolism
Drugs
Descripción
Sumario:Targeting brain lipid metabolism is a promising strategy to regulate the energy balance and fight metabolic diseases such as obesity. The development of stable platforms for selective delivery of drugs, particularly to the hypothalamus, is a challenge but a possible solution for these metabolic diseases. Attenuating fatty acid oxidation in the hypothalamus via CPT1A inhibition leads to satiety, but this target is difficult to reach in vivo with the current drugs. We propose using an advanced crosslinked polymeric micelle-type nanomedicine that can stably load the CPT1A inhibitor C75-CoA for in vivo control of the energy balance. Central adminis- tration of the nanomedicine induced a rapid attenuation of food intake and body weight in mice via regu- lation of appetite-related neuropeptides and neuronal activation of specific hypothalamic regions driving changes in the liver and adipose tissue. This nanomedicine targeting brain lipid metabolism was successful in the modulation of food intake and peripheral metabolism in mice.